Skip to main content
Equibles
VYCO logo

VYCO · Vycor Medical Inc · Metrics

Track VYCO — free

Use VYCO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VYCO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.04 At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has incurred losses since its inception, including a net loss of $2,180 for the six months ended June 30, 2026 and has not generated sufficient positive cash flows from operations. As of June 30, 2026 the Company had a working capital deficiency of $4,294,543 which includes related party liabilities of $3,800,538. These conditions, among others, raise substantial doubt regarding our ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.27M
Shares
33.37M
Volume · Oct 20 63.8K Avg daily vol (8 sessions) 57.26K

VYCO metrics

49 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.04
Market cap
$1.27M

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
—
Price change (3M)
-4.3%
Price change (6M)
-29.5%
Price change (YTD)
-44.6%
Price change (1Y)
-48.1%
Trailing year
Price change (5Y)
—
52-week high
$0.20
52-week low
$0.05
Change from 52-week high
-66.5%
Change from 52-week low
+34.0%
Annualized volatility
218.4%
Annualized volatility (3M)
—
Beta
—
RSI (14D)
47.6
Price vs SMA 50
-20.8%
Price vs SMA 200
-35.5%
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
33.37M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.2×
reciprocal yield 80.8%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
36.4
reciprocal yield 2.7%
Earnings yield
-2.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
83.4%
Operating margin
2.7%
Trailing 12 months
Net margin
-3.3%
Gross profit (TTM)
$1.51M
Operating profit (TTM)
$48,219
Net income (TTM)
−$59,930
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.00
Book value per share
$-0.12

Growth

11 metrics
Revenue growth YoY
-15.7%
Year over year
Net income growth YoY
-193.3%
Revenue (TTM)
$1.81M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-13.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+15.1%
Revenue CAGR (5Y)
+10.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-7.4%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
$106,842
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$158,907
Total assets
$813,174
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$61,384
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
$1.40M
Stock compensation (TTM)
$48,838
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement
Days to cover
—
Short-squeeze score
20 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1424768 CUSIP 92921M203 Visit website Investor relations